Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2019-01-07 Regulatory Filings
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting "Other Events" related to a Safety Review Committee endorsement and a press release dated January 7, 2019. There is no detailed financial data, no full financial statements, or comprehensive report content. The document is relatively short (3770 characters) and primarily serves as an announcement of an event and a press release. Therefore, it is not an Annual Report, Earnings Release, or Interim Report. It is a regulatory announcement of a corporate event, fitting the category of Regulatory Filings (RNS).
2019-01-07 English
Regulatory Filings 2018
Regulatory Filings
2018-12-20 English
4
Director's Dealing
2018-12-20 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is under Item 5.02, which announces the departure of a Chief Technology Officer, and Item 7.01, which references a press release about this departure. There are no financial statements or detailed financial data presented. The document primarily announces a change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3838 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2018-12-12 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from Adaptimmune Therapeutics plc responding to comments from the SEC Division of Corporation Finance staff regarding the company's previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and Quarterly Report on Form 10-Q for the period ended June 30, 2018. The letter addresses specific accounting and disclosure issues related to revenue recognition and milestone payments under a collaboration agreement. It references the 10-K and 10-Q filings but does not itself contain the full annual report or quarterly report financial statements or substantive financial data. Instead, it is a correspondence letter responding to regulatory comments. The document length is 7,155 characters, which is relatively short and consistent with a comment response letter rather than a full report. According to the classification rules, such correspondence responding to SEC comment letters is best classified as a Regulatory Filing (RNS), as it does not constitute the actual annual report or quarterly report but is a regulatory communication related to those filings.
2018-12-03 English
Regulatory Filings 2018
Regulatory Filings
2018-11-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.